An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Takeda
- Study ID
- NCT02497469
- Phase
- PHASE3
- Status
- Completed
Conditions
- Colitis, Ulcerative
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Vedolizumab — DRUGVedolizumab infusion
- Adalimumab placebo — DRUGAdalimumab placebo-matching injection
- Adalimumab — DRUGAdalimumab injection
- Vedolizumab placebo — DRUGVedolizumab placebo-matching infusion
Study Details
The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.
Key Dates
- Start date
- Jun 29, 2015
- Status verified
- Jan 2020
- Primary completion
- Sep 26, 2018
- Completion
- Jan 18, 2019
Study Design
- Enrollment
- 771 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Vedolizumab IV 300 mgVedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
- Active Comparator: Adalimumab SC 160/80/40 mgAdalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
Primary Outcome Measure
Percentage of Participants Who Achieved Clinical Remission [ Time Frame: Week 52 ]
Locations (77)
Find similar trials in Mobile, AL
By research site
IMC - Diagnostic and Medical Clinic· Mobile, ALArizona Arthritis & Rheumatology Research, PLLC· Phoenix, AZArkansas Primary Care Clinic, PA· Little Rock, ARWCCT Global (PH 1 Unit)· Costa Mesa, CACalifornia Medical Research Associates Inc.· Northridge, CASutter Institute for Medical Research· Sacramento, CA
Related Studies
- A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative ColitisRecruiting · Janssen Scientific Affairs, LLC · Portsmouth, Virginia
- Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese PatientsPHASE2 · Recruiting · University of California, San Diego · La Jolla, California
- A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisPHASE2/PHASE3 · Recruiting · Bristol-Myers Squibb · Phoenix, Arizona
- An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative ColitisRecruiting · Pfizer · Mesa, Arizona